EPA

Constitutional Limits to Independent Agencies and Central Banks: A Mini-Course With Paul Tucker (Part 2)

The Federal Reserve and the ECB have been taking unprecedented steps to react to the financial impact of Covid-19. To frame the debate around the...

Editors’ Briefing: This Week in Political Economy (June 30–July 7)

Scott Pruitt resigns from the EPA; a new report finds that digital platforms are not fully complying with the EU’s new privacy rules; Google,...

Editors’ Briefing: On Our Radar This Week (April 1–April 7)

This week in political economy.       Facebook acknowledged this week that the Cambridge Analytica data breach affected 87 million users (reportedly including 2.7 million Europeans)—37...

Editors’ Briefing: On Our Radar This Week (March 24-March 31)

This week in political economy.       Still mired in the Cambridge Analytica scandal, Facebook’s terrible month became worse this week after BuzzFeed published a 2016...

LATEST NEWS

Why Privacy Experts Need a Place at the Antitrust Table

Antitrust enforcers have tended to stay narrowly “in their lane,” failing to engage with how data is collected and used by digital...

Assessing George Stigler’s Economic Theory of Regulation

Despite its flaws and limitations, Stigler’s seminal article on the theory of economic regulation remains an important piece of scholarship worthy of...

“Old Chicago” and Freiburg: Why Ordoliberalism Was No “German Oddity”

Both the Chicago and Freiburg schools faced systemic fragility as the crucial property of societal orders. It was this fragility that served...

The Many Faces of Stigler’s Theory of Economic Regulation: Interest Group Politics Still Thrives—But Industry Often Comes Second

Stigler treats industry groups as the heavyweights in regulatory contests. But surprisingly often groups of farmers and workers knock them for a...

Why the FTC Should Consider Size in Drug Mergers

Large pharmaceutical firms retain their dominance through size-related advantages in three areas: contracting, marketing and selling, and financing. When reviewing pharmaceutical mergers,...